Cholesterol

Fuatilia
Illustration of Mayo Clinic study revealing 90% gap in genetic screening for familial hypercholesterolemia, featuring lab scientists, DNA data, heart plaque model, and screening call-to-action.
Àwòrán tí AI ṣe

Mayo Clinic study finds major gaps in genetic screening for inherited high cholesterol

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

A large Mayo Clinic study reports that current guidelines fail to detect nearly 90% of people with familial hypercholesterolemia, a common inherited cause of dangerously high cholesterol and early heart disease. Researchers analyzed exome data from more than 84,000 participants and found that most would not have been selected for standard genetic testing. Expanding routine DNA screening, they say, could help identify at-risk individuals earlier and prevent severe cardiovascular outcomes.

An experimental oral pill called enlicitide lowered LDL cholesterol by about 60% in a large phase three clinical trial, according to results published in The New England Journal of Medicine. The trial, led by Dr. Ann Marie Navar at UT Southwestern Medical Center and sponsored by Merck, involved 2,909 participants mostly already on statins. If approved, the daily pill could improve access to effective cholesterol treatment.

Ti AI ṣe iroyin

A clinical trial from the University of Bonn shows that consuming mostly oatmeal for two days can reduce harmful LDL cholesterol by 10 percent in people with metabolic syndrome. The benefits, including changes in gut bacteria, persisted for six weeks. Participants also experienced modest weight loss and lower blood pressure.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ